Dice Therapeutics (DICE) stock skyrocketed to a record high Tuesday after the biotech company unveiled promising early-stage test results for a psoriasis pill.
In premarket trading on today's stock market, shares of Dice stock soared 92.7% near 47.50.
Dice Chief Executive Kevin Judice says the results suggest Dice's DC-806 could be a best-in-class oral treatment for psoriasis.
After four weeks of treatment, patients showed a 43.7% decline in symptoms on a scale known as PASI, or psoriasis area and severity index. In comparison, placebo recipients had a 13.3% decline.
Now, the company is planning a midstage study beginning in the first half of 2023. Based on the promising data, Dice could also look at testing DC-806 in related diseases, Judice said in a written statement.
Dice Stock's Recent Yo-Yo
Dice's drug works by blocking interleukin-17, a substance in the body tied to inflammation.
The company tested DC-806 in three groups. Two groups of healthy volunteers received different dosages. Dice also showed its first proof-of-concept results in 32 patients with psoriasis. Of the latter group, eight patients received the highest dose and had a nearly 44% decline in symptoms.
In response, Dice stock topped its highest-ever point. Shares began trading in September 2021.
Dice noted the drug had "an excellent safety profile across all dose groups." There were no serious side effects, no incidents that prompted Dice to pull back the dosage, no treatment-related dropouts in the study and no clinically significant changes in patients' blood tests.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.